Syneos Health adds Barbara Bodem and Alfonso Zulueta to its Board as Independent Directors

– USA, NC –  Syneos Health (Nasdaq: SYNH), the only fully integrated biopharmaceutical solutions organization, today announced the appointments of Barbara Bodem and Alfonso Zulueta to its Board as Independent Directors, bringing the Board to 11 directors, 10 independent.

“We are excited to welcome Barbara and Alfonso to the Syneos Health Board. Barbara’s deep financial expertise combined with Alfonso’s expansive industry knowledge and international experience bring important perspectives to an already strong Board. These two leaders will enhance the composition of our Board and support continued successful oversight of our strategy as we speed our customers’ delivery of important therapies to patients,” said Board Chair, John Dineen.

Ms. Bodem will join the Audit Committee.

About Barbara W. Bodem

Ms. Bodem served as the SVP and CFO at Hillrom, a global medical technology company, from 2018 until its acquisition by Baxter International Inc. in 2021. She previously served as the SVP of Finance at Mallinckrodt Pharmaceuticals, a pharmaceutical manufacturer, from 2015 to 2018. She has also served in senior finance roles for Hospira, Inc. and Eli Lilly and Company.

Ms. Bodem currently serves on the board of directors of Turning Point Therapeutics, Inc. (Nasdaq: TPTX), a clinical-stage precision oncology company, where she serves as Chair of the Audit Committee and as a member of the Compensation Committee.

She received both her Bachelor of Science in Finance and MBA from Indiana University.

About Alfonso G. Zulueta

Mr. Zulueta has over three decades of experience in global strategic and leadership roles within large pharma, specifically with Eli Lilly and Company. At Eli Lilly, he held key senior positions including VP of Global Marketing, President of Global Oncology and Critical Care Products, and most recently as President of International responsible for all geographies outside the United States and Canada from 2017 until his retirement at the end of 2021. He was a corporate officer and member of Eli Lilly and Company’s executive committee.

Mr. Zulueta currently serves on the board of directors of CTS Corporation (NYSE: CTS), a global manufacturer of sensors, connectivity components, and actuators, where he serves on the Audit Committee; Compensation Committee; and Nominating, Governance, and Sustainability Committee. He also previously served as a member of the board of the European Federation of Pharmaceutical Industries and Associations, and the US-Japan Business Council.

He received his Bachelor of Arts from De La Salle University in the Philippines, and his MBA from Colgate Darden Graduate School of Business Administration at the University of Virginia.

About Syneos Health

Syneos Health is the only fully integrated biopharmaceutical solutions organization purpose-built to accelerate customer success. We lead with a product development mindset, strategically blending clinical development, medical affairs, and commercial capabilities to address modern market realities.

We bring together approximately 28,000 minds, across more than 110 countries, with a deep understanding of patient and physician behaviors and market dynamics. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients.

Syneos Health supports a diverse, equitable, and inclusive culture that cares for colleagues, customers, patients, communities, and the environment.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team